The Great Reshoring: US Captures 74% of CDMO Investment

PharmaSource analysis of 732 industry announcements reveals massive investment in U.S. capacity, with partnerships dominating the news cycle and advanced therapy manufacturing reaching industrial scale

The pharmaceutical contract manufacturing landscape underwent a fundamental readjustment in 2025, marked by record investment flows, accelerated U.S. reshoring, and a decisive shift toward integrated technology platforms.

In this episode, PharmaSource's very own Tamnna Thakur sits down with Editor Dora Wells to break down the year's most significant trends. From the $18.48 billion that poured into U.S. facilities to WuXi Biologics' 20 announcements despite regulatory headwinds. They analyze what the 732 tracked announcements reveal about where the industry is heading.

Read more.